logo
Overview
Discover
Watchlists
Portfolios
Heatmap
Sectors
Trendscore
Performers
Alerts
Options
Earnings
Screeners
Scanners
Backtests
Strategies
Comparisons
Charts
Sign in
Sectors
LVTX
LAVA Therapeutics N.V.
1.74
2 x 1.31
2 x 2.08
bid
ask
+
0.00
0.00%
04:00 PM
timesize
Ytd82.97%
1y8.75%
1.62
day range
1.82
0.85
52 week range
2.00
Open1.81Prev Close1.74Low1.62High1.82Mkt Cap45.77M
Vol0.00Avg Vol346.59KEPS-0.87P/E-2.00Forward P/E-0.51
Beta0.50Short Ratio0.41Inst. Own31.88%DividendN/ADiv YieldN/A
Ex Div DateN/AEarningN/A50-d Avg1.59200-d Avg1.391yr Est2.32

LVTX News

LAVA Therapeutics N.V. (NASDAQ:LVTX) Given Consensus Recommendation of “Reduce” by Analysts
defenseworld.net
LAVA Therapeutics N.V. (NASDAQ:LVTX) Given Consensus Recommendation of “Reduce” by Analysts

LAVA Therapeutics N.V. (NASDAQ: LVTX - Get Free Report) has received an average rating of "Reduce" f

Brokerages Set LAVA Therapeutics N.V. (NASDAQ:LVTX) PT at $2.69
defenseworld.net
Brokerages Set LAVA Therapeutics N.V. (NASDAQ:LVTX) PT at $2.69

LAVA Therapeutics N.V. (NASDAQ: LVTX - Get Free Report) has been assigned a consensus rating of "Red

Robert Bruce's Strategic Moves: AT&T Inc. Sees a -1.41% Portfolio Impact
gurufocus.com
Robert Bruce's Strategic Moves: AT&T Inc. Sees a -1.41% Portfolio Impact

Insightful Analysis of Robert Bruce (Trades, Portfolio)'s Third Quarter 2025 13F Filing Robert Bruce

LAVA Announces Exceeding Minimum Condition in Tender Offer and Intent to Delist from Nasdaq
globenewswire.com
LAVA Announces Exceeding Minimum Condition in Tender Offer and Intent to Delist from Nasdaq

UTRECHT, The Netherlands, and PHILADELPHIA, Nov. 13, 2025 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V.

LAVA Therapeutics N.V. Shareholders are Reminded to Tender Shares for XOMA Royalty Transaction Before November 12, 2025 Deadline
globenewswire.com
LAVA Therapeutics N.V. Shareholders are Reminded to Tender Shares for XOMA Royalty Transaction Befor

UTRECHT, The Netherlands and PHILADELPHIA, Nov. 10, 2025 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V.

Shareholder Alert: The Ademi Firm investigates whether LAVA Therapeutics N.V. is obtaining a Fair Price for its Public Shareholders in the Amendment to the Purchase Agreement
prnewswire.com
Shareholder Alert: The Ademi Firm investigates whether LAVA Therapeutics N.V. is obtaining a Fair Pr

MILWAUKEE , Oct. 20, 2025 /PRNewswire/ --The Ademi Firm is investigating Lava (Nasdaq: LVTX) for pos

LAVA Therapeutics to Move Extraordinary General Meeting to Early November 2025
globenewswire.com
LAVA Therapeutics to Move Extraordinary General Meeting to Early November 2025

Additional time enables LAVA Therapeutics to address potential liabilities and confirm net cash to b

LAVA Reports Second Quarter 2025 Financial Results and Provides Corporate Update
globenewswire.com
LAVA Reports Second Quarter 2025 Financial Results and Provides Corporate Update

UTRECHT, The Netherlands, and PHILADELPHIA, Aug. 13, 2025 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V.

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SCS, LVTX, ENZB on Behalf of Shareholders
prnewswire.com
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SCS, LVTX, ENZB on Behalf of Shareholders

NEW YORK , Aug. 8, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigat

SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of LAVA Therapeutics N.V. (NASDAQ: LVTX)
prnewswire.com
SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of LAVA Therapeutics N.V. (N

NEW YORK , Aug. 7, 2025 /PRNewswire/ -- Class Action Attorney  Juan Monteverde with Monteverde & Ass

LVTX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Lava Therapeutics N.V. Is Fair to Shareholders
businesswire.com
LVTX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Lava Therapeutics N.V. Is Fa

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether t

LAVA Reports First Quarter 2025 Financial Results, Provides Business Update
globenewswire.com
LAVA Reports First Quarter 2025 Financial Results, Provides Business Update

UTRECHT, The Netherlands and PHILADELPHIA, May 14, 2025 (GLOBE NEWSWIRE) --   LAVA Therapeutics N.V.

LAVA Therapeutics Granted Full Waiver for RVO Payment Obligation
globenewswire.com
LAVA Therapeutics Granted Full Waiver for RVO Payment Obligation

Exemption from the $5.1 million repayment obligation strengthens LAVA's balance sheet Underscores fo

LAVA Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update
globenewswire.com
LAVA Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update

UTRECHT, The Netherlands and PHILADELPHIA, March 28, 2025 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V.

Analyst Downgrades LAVA Therapeutics, Sees Pipeline Overhang
benzinga.com
Analyst Downgrades LAVA Therapeutics, Sees Pipeline Overhang

On Tuesday, LAVA Therapeutics N.V. LVTX initiated a process to review strategic options.

LAVA Doses First Patient in Phase 1 LAVA-1266 Study in Hematological Cancers
globenewswire.com
LAVA Doses First Patient in Phase 1 LAVA-1266 Study in Hematological Cancers

UTRECHT, The Netherlands and PHILADELPHIA, Jan. 10, 2025 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V.

LAVA Reports Third Quarter 2024 Financial Results and Announces Pipeline Reprioritization and Cash Runway Extension into 2027
globenewswire.com
LAVA Reports Third Quarter 2024 Financial Results and Announces Pipeline Reprioritization and Cash R

UTRECHT, The Netherlands and PHILADELPHIA, Dec. 10, 2024 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V.

LAVA Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
globenewswire.com
LAVA Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

UTRECHT, The Netherlands and PHILADELPHIA, Sept. 03, 2024 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V.

LAVA Reports Second Quarter 2024 Financial Results and Business Update
globenewswire.com
LAVA Reports Second Quarter 2024 Financial Results and Business Update

UTRECHT, The Netherlands and PHILADELPHIA, Aug. 20, 2024 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V.

benzinga.com
Why Aridis Pharmaceuticals Shares Plunged Around 30%; Here Are 81 Biggest Movers From Yesterday

Gainers

benzinga.com
Stocks That Hit 52-Week Lows On Friday

  On Friday, 1043 companies hit new 52-week lows.